SCHEMBL4865626

SCHEMBL4865626

Cc1cccc(C=CC(=O)c2ccccc2)c1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.58
MAPT P10636 6/20 0.58
NPC1 O15118 6/20 0.58
LMNA P02545 2/20 0.58
BCHE P06276 2/20 0.58
ALDH1A1 P00352 4/20 0.54
HPGD P15428 3/20 0.54
CYP3A4 P08684 1/20 0.54
MAOB P27338 2/20 0.53
CYP1B1 Q16678 2/20 0.53
PLIN1 O60240 1/20 0.53
TNFRSF1A P19438 1/20 0.53
ACHE P22303 1/20 0.53
RECQL P46063 1/20 0.53
PLIN5 Q00G26 1/20 0.53
ABHD5 Q8WTS1 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31398692 0.88 RAB9A (0.63) RAB9AMAPTNPC1LMNABCHE
SCHEMBL351853 0.88 RAB9A (0.63) RAB9AMAPTNPC1LMNABCHE
SCHEMBL7660164 0.88 RAB9A (0.63) RAB9AMAPTNPC1LMNABCHE
SCHEMBL1225684 0.88 RAB9A (0.63) RAB9AMAPTNPC1LMNABCHE
SCHEMBL11813963 0.87 MAPT (0.54) RAB9AMAPTNPC1LMNABCHE
Hydrochloric Acid SCHEMBL11814386 0.85 MAPT (0.53) RAB9AMAPTNPC1LMNABCHE
SCHEMBL28814889 0.85 PTGER1 (0.57) RAB9AMAPTNPC1LMNABCHE
SCHEMBL675700 0.85 PTGER1 (0.57) RAB9AMAPTNPC1LMNABCHE
SCHEMBL27621963 0.84 RAB9A (0.55) RAB9AMAPTNPC1LMNABCHE
SCHEMBL691503 0.82 CA1 (0.53) MAPTSMN1; SMN2NFKB1KDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115141621-A Oil-based fracturing fluid, multi-stage fracturing method and method for online monitoring productivity of reservoir intervals 中国石油化工股份有限公司 2022-10-04 CN claimed
CN-104055755-A Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone in preparation of antitumor drugs UNIV ZHEJIANG SCIENCES 2014-09-24 CN claimed
CN-102068420-B Application of 2',4'-dihydroxy-6'-methoxyl-3',5'-dimethyl chalcone in preparation of medicaments for treating liver diseases UNIV EAST CHINA SCIENCE & TECH 2012-07-04 CN claimed
CN-102068420-A Application of 2',4'-dihydroxy-6'-methoxyl-3',5'-dimethyl chalcone in preparation of medicaments for treating liver diseases UNIV EAST CHINA SCIENCE & TECH 2011-05-25 CN claimed
CN-101259118-B Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist GUANGZHOU INST BIOMED & HEALTH 2010-06-16 CN claimed
CN-101716166-A Applications of 2', 4'-dihydroxyl-6'-methoxyl-3', 5'-dimethyl chalcone UNIV EAST CHINA SCIENCE & TECH 2010-06-02 CN claimed
CN-101259118-A Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist GUANGZHOU INST BIOMED & HEALTH (CN) 2008-09-10 CN claimed
WO-2023177194-A1 NOVEL DIMETHYLCHALCONE DERIVATIVES 중앙대학교 산학협력단 2023-09-21 WO disclosed
WO-2023177191-A1 COMPOSITION FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING DIMETHYLCHALCONE DERIVATIVE AS ACTIVE INGREDIENT 서울대학교 산학협력단 2023-09-21 WO disclosed
WO-2023177191-A1 COMPOSITION FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING DIMETHYLCHALCONE DERIVATIVE AS ACTIVE INGREDIENT 서울대학교 산학협력단 2023-09-21 WO disclosed
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) 2023-08-10 US disclosed
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) 2023-08-10 US disclosed
CN-115400106-A Application of natural compound and composition thereof in removing senescent cells 清华大学 2022-11-29 CN disclosed
CN-101259118-A Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist GUANGZHOU INST BIOMED & HEALTH (CN) 2008-09-10 CN disclosed
CN-101048651-A Multifunctional reference system for use in analyte detection by fluorescence HOFFMANN LA ROCHE (CH) 2007-10-03 CN disclosed
CN-1275923-C Use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalkone as reversing agent for resistance of multiple tumours drugs UNIV EAST CHINA SCIENCE & TECH (CN) 2006-09-20 CN disclosed
CN-1680248-A Use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalkone as reversing agent for resistance of multiple tumours drugs HUADONG SCIENCE & ENGINEERING (CN) 2005-10-12 CN disclosed
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2005-07-07 US disclosed
CN-1454895-A Use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone for preparing anticancer medicine TUMOUR PREVENTION AND TREAT CT (CN) 2003-11-12 CN disclosed
CN-1075632-A Alkoxylated phenyl and coumarin derivative and application thereof SCHAPER & BRUEMMER GMBH (DE) 1993-09-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE LIPC, PC, CYP27A1 RAB9A 3306/4885MAPT 1563/4885NPC1 189/4885
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 RAB9A 2231/4885MAPT 341/4885NPC1 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.